Ocugen (OCGN) Income from Continuing Operations (2014 - 2026)
Ocugen posted quarterly Income from Continuing Operations of 19059000.0 for Q1 2026, down 23.3% year-on-year from 24847265.08 in Q1 2025, and down 4.69% on a QoQ basis from 18205000.0 in Q4 2025.
Ocugen (OCGN) has 13 years of Income from Continuing Operations data on file, last reported at 19059000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 23.3% year-over-year to 19059000.0; the trailing twelve-month figure through Mar 2026 stood at 70849000.0 (down 22.71% YoY), and the FY2025 full-year result was 67182000.0, down 23.97% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 19059000.0, down from 18205000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 11525000.0 in Q4 2023 and bottomed at 23540000.0 in Q2 2023.
- The 5-year median for Income from Continuing Operations is 18035000.0 (2023), against an average of 17088176.47.
- The widest annual swing landed in 2022, when Income from Continuing Operations slumped 168.9%; it then surged 47.47% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 21939000.0 in 2022, then surged by 47.47% to 11525000.0 in 2023, then dropped by 21.76% to 14033000.0 in 2024, then slipped by 29.73% to 18205000.0 in 2025, then declined by 4.69% to 19059000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 19059000.0 (Q1 2026), 18205000.0 (Q4 2025), and 18732000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Ocugen | 452.01 Mn | 452.01 Mn | - | -19.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.06 Mn |
| Dec 31, 2025 | -18.21 Mn |
| Sep 30, 2025 | -18.73 Mn |
| Jun 30, 2025 | -14.85 Mn |
| Mar 31, 2025 | -15.46 Mn |
| Dec 31, 2024 | -14.03 Mn |
| Sep 30, 2024 | -12.97 Mn |
| Jun 30, 2024 | -15.28 Mn |
| Mar 31, 2024 | -11.91 Mn |
| Dec 31, 2023 | -11.53 Mn |
| Sep 30, 2023 | -12.43 Mn |
| Jun 30, 2023 | -23.54 Mn |
| Mar 31, 2023 | -18.04 Mn |
| Dec 31, 2022 | -21.94 Mn |
| Sep 30, 2022 | -21.92 Mn |
| Jun 30, 2022 | -21.58 Mn |
| Mar 31, 2022 | -19.03 Mn |
| Dec 31, 2021 | -14.58 Mn |
| Sep 30, 2021 | -10.76 Mn |
| Jun 30, 2021 | -25.62 Mn |
| Mar 31, 2021 | -7.08 Mn |
| Dec 31, 2020 | -3.77 Mn |
| Sep 30, 2020 | -10.47 Mn |
| Jun 30, 2020 | -3.61 Mn |
| Mar 31, 2020 | -3.94 Mn |
| Dec 31, 2019 | -4.29 Mn |
| Sep 30, 2019 | -3.51 Mn |
| Jun 30, 2019 | -2.59 Mn |
| Mar 31, 2019 | -5.54 Mn |
| Dec 31, 2018 | -6.40 Mn |
| Sep 30, 2018 | -3.40 Mn |
| Jun 30, 2018 | -7.25 Mn |
| Mar 31, 2018 | -6.06 Mn |
| Dec 31, 2017 | -6.01 Mn |
| Sep 30, 2017 | -5.67 Mn |
| Jun 30, 2017 | -6.33 Mn |
| Mar 31, 2017 | -6.80 Mn |
| Dec 31, 2016 | -7.92 Mn |
| Sep 30, 2016 | -6.69 Mn |
| Jun 30, 2016 | -7.99 Mn |
| Mar 31, 2016 | -7.84 Mn |
| Dec 31, 2015 | -8.34 Mn |
| Sep 30, 2015 | -8.06 Mn |
| Jun 30, 2015 | -7.62 Mn |
| Mar 31, 2015 | -7.94 Mn |
| Dec 31, 2014 | -6.67 Mn |
| Sep 30, 2014 | -14.96 Mn |
| Jun 30, 2014 | -6.01 Mn |
| Mar 31, 2014 | -5.17 Mn |